At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VVOS Vivos Therapeutics
Post-Mkt 07-01 16:24:02 EDT
0.4983
+0.0438
+9.64%
盘后0.4801
-0.0182-3.65%
16:19 EDT
High0.5263Low0.4600Vol437.34K
Open0.4700D1 Closing0.4545Amplitude14.59%
Mkt Cap6.92MTradable Cap6.00MTotal Shares13.89M
T/O215.25KT/O Rate3.63%Tradable Shares12.05M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vivos Therapeutics says Vida oral appliance improves insomnia in study
TIPRANKS  ·  06-30 21:35
Vivos Therapeutics says Vida oral appliance improves insomnia in study
Vivos Says Study Shows Vida Oral Appliance Cuts Insomnia Severity in All 37 Patients
Reuters  ·  06-30 20:45
Vivos Says Study Shows Vida Oral Appliance Cuts Insomnia Severity in All 37 Patients
Vivos Therapeutics Extends Debt-for-Equity Conversion Timeline
TIPRANKS  ·  06-26
Vivos Therapeutics Extends Debt-for-Equity Conversion Timeline
Vivos Therapeutics Extends Streeterville Debt-to-equity Conversion Deal Through Aug. 31, 2026
Reuters  ·  06-26
Vivos Therapeutics Extends Streeterville Debt-to-equity Conversion Deal Through Aug. 31, 2026
Vivos Therapeutics Extends Financing Agreement With Streeterville Through August
MT Newswires Live  ·  06-22
Vivos Therapeutics Extends Financing Agreement With Streeterville Through August
Vivos Therapeutics extends Streeterville deal to convert up to $4.5 million debt into equity
Reuters  ·  06-22
Vivos Therapeutics extends Streeterville deal to convert up to $4.5 million debt into equity
Vivos Therapeutics - Streeterville Extends Agreement to Aug 31, 2026, Reaffirms $4.5 Mln Debt Conversion Commitment
THOMSON REUTERS  ·  06-22
Vivos Therapeutics - Streeterville Extends Agreement to Aug 31, 2026, Reaffirms $4.5 Mln Debt Conversion Commitment
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
THOMSON REUTERS  ·  06-22
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
Vivos Therapeutics Plans Rights Offering to Existing Shareholders
TIPRANKS  ·  06-17
Vivos Therapeutics Plans Rights Offering to Existing Shareholders
Vivos Therapeutics plans registration statement for transferable shareholder rights offering
Reuters  ·  06-17
Vivos Therapeutics plans registration statement for transferable shareholder rights offering
Vivos Therapeutics partners with South Palm Cardiovascular to launch Florida sleep apnea, insomnia services venture
Reuters  ·  06-16
Vivos Therapeutics partners with South Palm Cardiovascular to launch Florida sleep apnea, insomnia services venture
Vivos Therapeutics Plans to File for Proposed Rights Offering
MT Newswires Live  ·  06-11
Vivos Therapeutics Plans to File for Proposed Rights Offering
Vivos Therapeutics plans SEC registration filing for proposed transferable rights offering
Reuters  ·  06-11
Vivos Therapeutics plans SEC registration filing for proposed transferable rights offering
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
THOMSON REUTERS  ·  06-11
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
Vivos Therapeutics enters pact with South Palm Cardiovascular Associates
TIPRANKS  ·  06-10
Vivos Therapeutics enters pact with South Palm Cardiovascular Associates
Vivos Therapeutics partners with South Palm Cardiovascular to launch Florida sleep apnea, insomnia services venture
Reuters  ·  06-10
Vivos Therapeutics partners with South Palm Cardiovascular to launch Florida sleep apnea, insomnia services venture
Vivos Therapeutics Announces Key Collaboration Agreement With Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
THOMSON REUTERS  ·  06-10
Vivos Therapeutics Announces Key Collaboration Agreement With Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
Vivos Therapeutics CEO to present at Small Cap Showcase & WTR Insights
Reuters  ·  06-09
Vivos Therapeutics CEO to present at Small Cap Showcase & WTR Insights
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
GlobeNewswire  ·  06-09
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
Sector Update: Healthcare Stocks Higher Late Afternoon
MT Newswires Live  ·  06-06
Sector Update: Healthcare Stocks Higher Late Afternoon

Introduction

Company Name.
Vivos Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.
Issue price:
--